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Abstract

Francisella tularensis is an intracellular pathogen that has been classified as a category “A” bioterrorism
agent by the Centers For Disease Control. To date, there is no approved vaccine to provide protection
against this pathogen. Previous in vivo studies with mice have shown that a mucosally targeted vaccine
preparation of inactivated F. tularensis (iFt) adjuvanted with Cholera toxin “B” (CTB), successfully
granted full protection against a less virulent strain (FT LVS) of the bacterium and provided partial
protection against a more virulent strain (SchuS4). However, the mechanisms of this protection are not
fully understood. In this present study, an in vitro system was utilized to further elucidate the
mechanisms that drive protection against lethal F. tularensis challenge in iFt+CTB mucosally immunized
mice. Specifically, the focus was directed towards determining the effects of iFt+CTB on macrophages,
the common host of F. tularensis, and their ability to present antigen to naïve T-cells, express
costimulatory molecules, and produce pro-inflammatory cytokines. We found that RAW264.7 cells, a
murine macrophage cell line, responded to treatment with iFt+CTB by an increased secretion of the proinflammatory cytokines IL-6 and TNF-α. It was also determined that treatment with iFt+CTB upregulated the expression of TLR4 on the macrophage cell surface. The effects of iFt+CTB treatment were
shown to increase the expression of both costimulatory molecules B7.1 and B7.2 on the macrophage cell
surface. Furthermore, we found that iFt+CTB enhanced the ability of macrophages to present antigen to
a FT-specific T-cell hybridoma cell line. These findings allow us to elucidate in part, the mechanisms of
protection against F. tularensis challenge in iFt+CTB immunized mice.
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Introduction
1.1 Introduction to Vaccines
Vaccines are one of the most successful achievements of modern medicine. Many pathogens
that have plagued mankind throughout history, such as polio, measles, small pox, and diptheria,
have been controlled or eradicated through successful vaccination programs. Since Edward
Jenner pioneered the first vaccine in 1796 using cowpox material to protect against smallpox,
vaccination has truly become a modern marvel of human ingenuity and cleverness.
There are many methods that have been successfully used to grant protection from various
bacteria, viruses, and toxins. Immunization can be granted through either passive or active
means, in a natural or, as is the case of a vaccine, an artificial manner (Clem, 2011). Passive
immunization occurs with the transfer of preformed antibodies to an unimmunized individual,
conferring a rapid, effective, but temporary immunity. This type of immunity can be acquired
naturally through the passage of maternal antibodies to a fetus through the placenta, and later
through breast milk. Artificial passive immunity, on the other hand, is transmitted through
delivering functional preformed antibodies to an unimmunized individual, such as through the
use of antivenin serums that contain preformed antibodies designed to target a specific venom
(Clem, 2011). Active immunity stimulates the adaptive immune system, subsequently
conferring long-term memory against a pathogen, through the generation of long-lived memory
T-cells and B-cells. These cells, known as lymphocytes, “remember” a specific previously
encountered antigen and are able to respond more effectively and rapidly compared to the
primary challenge. Natural active immunity is achieved through the process of infection with
the actual pathogen followed by its successful clearance from the body. Vaccines are able to
1

grant active immunity by an artificial means, wherein they mimic the stimulation necessary to
elicit an adaptive immune response, thereby generating immunological memory, without
producing disease (Clem, 2011).

1.2 The Systemic Immune System and the Generation of Immunological Memory
Successful vaccines must generate immunological memory (Clem, 2011). A vaccine must safely
provoke a deliberate and strong immune response, thereby activating the appropriate branch
of the adaptive immune system, resulting in the generation of memory (Kindt et al., 2007).
However, in most cases it is the innate branch of the immune system that first encounters the
antigen.
The innate immune system is the first line of defense against invading pathogens, specifically
through its anatomical and chemical barriers, as well as through a collection of cells and
molecules that mediate inflammation. The cells of innate immunity recognize foreign
molecular patterns, by utilizing their pattern recognition receptors (PRRs). PRRs, although not
specific to a particular pathogen, can recognize pathogen-associated molecular patterns
(PAMPs) (Clem, 2011). Recognition of PAMPS by PRRs leads to the development of an
inflammatory response, which entails complement activation, opsonization, cytokine release,
and phagocyte activation. Macrophages and dendritic cells are types of innate cells that, upon
activation, have the ability to recruit the assistance of the adaptive immune system via antigen
presentation. Antigen presentation is crucial for the successful activation of, what is perhaps
the most pivotal cell of the adaptive response, the CD4+ T-helper cell.
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On their own, T-cells are unable to recognize free antigens. They depend upon the efforts of
antigen presenting cells (APCs) to process and present antigens directly to them, in association
with the major histocompatibility complex (MHC). CD4+ T-helper cells only recognize antigens
presented on MHC class II molecules, which are found exclusively on these antigen presenting
cells (Clem, 2011). Antigen presenting cells (APCs) provide the vital bridge to the adaptive
immune system and the generation of immunological memory. There are only three
professional APCs that possess the necessary surface molecules to activate naïve CD4+ T-cells:
Macrophages, B-cells, and dendritic cells. These three APCs not only express MHC class II, but
they also express the costimulatory molecules, B7-1 (CD80) and B7-2 (CD86), both of which
provide the required second signal for T-cell activation (Kindt et al., 2007). APCs both process
and make direct contact with antigens in one of two ways. The first, is via an exogenous route
that allows antigens from outside the cells to be phagocytosed and presented via MHC class II.
The second, is via an endogenous route where antigens from within the cell, such as viral
proteins, are processed and presented to CD8+ T-cells via MHC class I. All nucleated cells have
the ability to present antigens, via the endogenous route, on a class I MHC molecule, indicating
intracellular infection and directing the cytotoxicity of CD8+ T-cells. However, it is only the
professional APCs that have the unique ability to process antigens through the exogenous
route, presenting on MHC class II molecules which are recognized by CD4+ T-cells. After the
APC successfully activates the naïve T-cell, the lymphocyte begins to proliferate and
differentiate into memory and effector cells.
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1.3 Vaccination Strategies and Constraints
Many successful vaccines, including the Sabin polio vaccine, are composed of live, attenuated,
whole microorganisms (Kindt et al., 2007). Live attenuated vaccines cause a strong immune
response that will result in lifelong immunity. However, there are safety concerns with delivery
of live pathogens into a healthy individual. As was the case with the Sabin vaccine, there is a
risk of attenuated pathogens reverting back to the virulent form, causing disease after
vaccination. Inactivated, or killed whole microorganism vaccines provide a safer alternative
than that of live attenuated. Unfortunately, they do not stimulate a robust cellular immune
response, and thus typically require booster shots. Other effective vaccines have been
developed that utilize inactivated toxins, known as toxoids. The diphtheria vaccine, for
example, is composed of inactivated versions of bacterial exotoxins that cause production of
neutralizing antibodies which, in turn, protect against the active form of the toxin. Subunit
vaccines exploit specific antigenic fragments of a pathogen in an effort to induce an immune
response, as has been successfully accomplished with the hepatitis B vaccine. Although subunit
vaccines offer safer protection, they often prove tremendously difficult to determine a
protective antigenic subunit, and then subsequently develop a vaccine.
Vaccines, in general, have seen an enormous amount of success in the past century. However,
conventional vaccine strategies have been pushed to their limitations, and have proven to offer
very limited protection against many pathogens, including HIV, tuberculosis, and malaria,
making it necessary to research more innovative immunizing strategies (Yuki and Kiyono, 2003).
The majority of successful vaccines to date are administered by injection, intramuscularly or
subcutaneously, conferring protective systemic immunity. Many pathogens however, gain
4

access to the body through mucosal surfaces via ingestion, inhalation, or sexual contact.
Traditional injectable vaccines fail to induce protective immunity at the mucosal surfaces,
leaving this critical route of entry vulnerable. Interestingly, mucosal vaccines, which are
administered at the mucosal surfaces, have been shown to generate systemic protection in
addition to mucosal immunity (Yuki and Kiyono, 2003). Mucosal vaccine systems may
ultimately prove superior by conferring this dual immunity, while additionally deterring
pathogens at the initial site of invasion. Unfortunately, most protein antigens that are
administered mucosally are very poor immunogens. Furthermore, to their own detriment, they
can induce immune tolerance, the opposite of the desired response (Yuki and Kiyono, 2003).
Development of mucosal vaccines has long been hindered by this phenomenon. Fortunately,
promising research has been focused on the development of safe mucosal adjuvants.
An added constraint in most vaccinations used today, both injectable and mucosal, is that they
elicit a strictly humoral protective response from the host (De Pascalis, 2012). Through a
variety of mechanisms, antibodies are proficient at controlling or limiting many types of
infection, however due to their inability to cross the plasma membrane their usefulness is
confined to outside the cell. Upon infection with an intracellular pathogen, such as Fracisella
tularensis, the value of antibody protection becomes diminished and cell-mediated immunity
takes a primary role in eradicating the invading microbe. The tactics of infection displayed by
intracellular parasites warrant the design of a vaccine that stimulates a cell-mediated immune
response. In addition to the activation of the specific branch of the immune system, a vaccine
that targets the initial site of infection would farther boost its potential for success. Most
pathogens gain access to the body through mucosal surfaces; for this reason, the mucosa has
5

evolved an almost entirely separate immune system that has yet to be thoroughly exploited by
vaccine developers.

1.4 The Mucosal Immune System
Mucosal surfaces of the gut, airway, and urogenital tract provide an interface between the
body’s tightly regulated interior environment and that of the continuously changing external
environment (Kraehenbuhl and Neutra, 1999). Mucosal membranes are consistently on the
frontline of exposure to potentially dangerous microorganisms, as well as a vast array of benign
normal flora. It is due to their inherent vulnerability that mucosal surfaces have developed a
localized component of the immune system. Specialized mucosal lymphoid tissues uniquely
uptake and process antigens, produce distinct immunoglobulins, and activate effector cells in a
manner that is nearly independent from the systemic immune system (Kraehenbuhl and
Neutra, 1999). The mucosal immune system can effectively be divided into distinct inductive
and effector sites (MacDonald et al., 2013) (see figure 1).
These inductive sites collectively known as mucosa-associated lymphoid tissue (MALT) are
comprised in a similar manner to lymph nodes. MALT houses B-cell follicles, interfollicular Tcell regions, and an assortment of antigen-presenting cells. Notably, MALT structures lack
afferent lymphatic vessels and must sample antigens directly from the mucosal surfaces.
Antigen sampling takes place through unique regions on the mucosal epithelium known as
follicle-associated epithelium (FAE) which covers the underlying mucosal lymphoid tissue.
There are three methods of antigen sampling that occurs in these inductive regions of MALT.
First, involves specialized epithelial cells known as microfold (M) cells which are located
6

Figure 1
Overview of the human mucosal immune system. Reprinted by permission from Macmillan
Publishers Ltd: Mucosal Immunology, 1(1), 32, Brandtzaeg, P., Kiyono, H., Pabst, R., & Rusell, M.
(2008). Terminology: nomenclature of mucosa-associated lymphoid tissue.
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exclusively in the FAE. M cells have the unique function of transporting antigenic material from
the lumen to dendritic cells (DCs), macrophages, and lymphocytes of the MALT waiting below
the epithelium (MacDonald et al., 2013). Besides M cell sampling, DCs have the ability to reach
their dendrites in between epithelial cells to directly capture antigens in the lumen. Thirdly,
immune complexes can transcytose through mucosal epithelial cells by means of the Fc
neonatal receptor. Once an antigen reaches the lymphoid tissue it may be presented by
various APCs to local lymphocytes, phagocytosed by resident macrophages, or brought to
lymph nodes via dendritic cells. Once in the possession of an antigen, DCs may activate T-cells
immediately in the subepithelial dome or they may migrate to regional lymph nodes.
Lymphocytes activated in MALT structures migrate through the lymphatic system and home in
on mucosal effector sites through the expression of various integrins and cell adhesion
molecules (CAMs) (MacDonald et al., 2013).
Mucosal effector sites are often populated by activated lymphocytes, macrophages, dendritic
cells, and granulocytes. Here, MALT derived mucosal plasma cells are the body’s largest
population of antibody secreting cells; predominantly IgA. These plasma cells produce enough
dimeric secretory IgA (SIgA) to effectively protect the majority of mucosal surfaces. Mucosal
macrophages are present through the entirety of the mucosa, where they actively neutralize
microorganisms, inert material, and apoptotic cells by phagocytosis. While the mucosal
immune system can be quite proficient at controlling a multitude of infections, it should be
noted that this system is not independent. It is closely associated with the systemic immune
system.
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1.5 Francisella tularensis
The causative agent of tularemia, Francisella tularensis, is a small gram-negative bacterium that
exists as a pleomorphic coccobacillus (Wong and Shapiro, 1999). It is a facultative intracellular
parasite that can survive and multiply within host macrophages, as well as within other cell
types (Harvey et al., 2007). There are two subspecies of Francisella tularensis, tularensis (biovar
A) and holarctica (biovar B) (Bitsaktsis et al., 2009). Of these subspecies, biovar A strains, such
as SchuS4, prove to be the most virulent in humans as well as other mammals. The first human
cases of tularemia were reported in 1907, and were found to be linked to the contact of wild
animals (Wong and Shapiro, 1999). This rural disease, which came to be known as "Rabbit
Fever", is most frequently contracted by hunters, trappers, veterinarians, livestock handlers,
and those who are frequently exposed to a variety of different species of mammals. Contact
with the bacterium’s preferred reservoir, wild rabbits of the genus: Sylvilagus, as well as bites
from arthropod vectors, such as the tick, are the most common causes of infection. F.
tularensis is an immensely durable organism. Its occurrence is found naturally within many
different species, including mammals, arthropods, and avians, as well as abiotic components of
the environment, such as water, mud, and animal feces. In the United States, tularemia is
endemic to Arkansas, Missouri, and Oklahoma, with the highest incidence of infection occurring
during the summer months (Harvey et al., 2007).
The Centers for Disease Control has classified F.tularensis as a category “A” bioterrorism agent
due to its ease of dissemination, its potential to substantially impact public health and induce
widespread panic, and the requirement of special action that would need to be undertaken by
public health officials, if such an event were to occur (Bioterrorism, www.bt.cdc.gov). In
9

addition to this, F. tularensis has become exceptionally well known for its potential to be
wielded as a weapon in biological warfare. During the 1930s and 1940s, numerous outbreaks
of waterborne tularemia in both Europe and the Soviet Union incited large epidemics that
brought widespread publicity to the potential threat of this organism if used as a biological
weapon (Dennis et al., 2001). During World War II, biological warfare research facilities in the
United States, Japan, and the Soviet Union began experimenting with the use of F. tularensis for
military purposes. The United States has since admitted to the development of weaponized F.
tularensis disseminating aerosols, during the 1950s and 1960s. In fact, for such purposes,
aerosol deployment of this organism would be the ideal delivery system. It is one of the most
infectious pathogenic bacteria known today, requiring the inhalation of as little as ten
organisms to cause disease (Dennis et al., 2001). The victims of such an attack would be readily
stricken with a severe, and often fatal, pneumonic form of tularemia. Once the pathogen has
been inhaled, it is able to quickly gain access to the body through the mucosal surfaces of the
respiratory tract, making its threat, and subsequent impact to public health and welfare all the
more severe. The development of a mucosal vaccine designed to combat F. tularensis is the
primary, if not ideal strategy that must be undertaken to protect against pneumonic tularemia
is to be successful. It is through the development of such a vaccine that protection at the
primary site of exposure to the pathogen can be achieved.

1.6 Vaccine adjuvants
During vaccine development it is imperative to elicit an immune response to the protective
antigen administered, but very few molecules are immunogenic when they contact mucosal
10

surfaces (Rappuoli et al., 1999). Adjuvants are substances that when mixed with, or conjugated
to, an antigen enhance the immunogenicity of that antigen. Generally, adjuvants cause the upregulation of costimulatory molecules, prolong antigen presence, increase local inflammation,
and stimulate proliferation of lymphocytes (Kindt et al., 2007). The most powerful mucosal
immunogens known to date are cholera toxin (CT), which we will focus on in this study, as well
as Escherichia coli heat-labile enterotoxin (LT) (Rappuoli et al., 1999). These molecules cause
the severe diarrhea seen in cholera and traveler’s diarrhea. The mucosal immune system is
able to recognize these toxins as a threat and mount a strong immune response against them.
CT and LT are very similar in structure, both of which consist of two subunits: a pentameric “B”
oligomer, which allows the toxin to bind to receptors on the surface of eukaryotic cells. The
other, an enzymatically active “A” subunit is responsible for toxicity. The toxic effects caused
by the intact cholera toxin molecule initiate when the cholera toxin B subunit (CTB) binds to the
ganglioside GM1, believed to be a major toxin receptor, which is located on the surface of a
host epithelial cell (Rappuoli et al., 1999). The “A” subunit is anchored to the “B” pentamer by
means of a trypsin sensitive loop, and a long alpha helix whose C-terminus enters the central
cavity of the “B” pentamer. After CTB binds to the GM1 ganglioside, the host cell internalizes
the toxin into vesicles; the holotoxin is then cleaved by proteases into its subunits within the
Golgi apparatus. The now enzymatically active “A” subunit translocates to the cytosol where it
acts as an ADP ribosylase on the alpha subunit of regulatory heterotrimeric G proteins, thus
inducing covalent adenylate cyclase activation. This persistent activation leads to abnormal
levels of the second messenger, cAMP, accumulating within the cell, which is related to the
induction of the profuse fluid expulsion seen in these debilitating diarrheal diseases.
11

The ability of enterotoxin molecules to generate such an intense mucosal response, in an
environment that tolerates most potential antigens, makes them of much interest to mucosal
vaccine research. The use of toxin molecules as adjuvants has shown promising results.
Nevertheless, they must be rendered safe by some method of separation of adjuvanticity from
toxicity. Past studies have shown that a nasal influenza vaccine employing an enterotoxin
adjuvant produced a significant number of cases of Bell’s palsy in vaccinees (Rhee and Lee,
2012). It has been suggested that the enterotoxin binds with high affinity to the GM1
ganglioside receptors of the olfactory nerves and begins to build up in the brain producing this
undesired side effect. Not all mechanisms of enterotoxin adjuvanticity are understood and
must be elucidated before additional clinical trials become a possibility.
A significant amount of research has been aimed at the immune modulating effects of cholera
toxin and its subunits. In the past, studies have cultured macrophage cell lines in the presence
of intact cholera toxin, reporting enhanced antigen presentation which ultimately leads to
elevated T-cell proliferation (Bromander et al., 1991). It was also determined that macrophages
cultured with CT produced elevated levels of the pro-inflammtory cytokine IL-1. The adjuvant
activity seen with intact cholera toxin was originally thought to be associated with its toxicity.
However, it was not until further studies had been undertaken that the pentameric “B” subunit
was determined to have no enzymatic activity and can function as an effective adjuvant alone
(Wu and Russell, 1998). Initially, the adjuvant effects of CTB were suspected to have been the
result of intact CT contamination in commercially available CTB stocks. In order to verify that
CTB alone could act as an adjuvant, an in vivo study involving mice was conducted at the
University of Alabama. There, the adjuvant effects of highly purified recombinant CTB to the
12

commercially available formula of CTB, and to a mixture of CTB/CT were compared. The results
demonstrated that intranasal administration of pure CTB functioned quite successfully as an
adjuvant, thus increasing the mucosal and systemic antibody response in treated mice (Wu and
Russell, 1998).

1.7 Use of CTB as a Vaccine Adjuvant in vitro
One mechanism of adjuvanticity of CTB can be attributed to its efficiency as a mucosal carrier
molecule, wherein antigens conjugated to CTB are effectively delivered to APCs through high
affinity binding to the GM1 ganglioside on APC surfaces (George-Chandy et al., 2001). In
addition to antigen delivery, CTB has also been shown to enhance the ability of antigen
presentation by APCs. In vitro studies have shown that antigens conjugated to CTB greatly
reduce the amount of antigen needed to stimulate a proliferative T-cell response and allow
macrophages to function as efficient APCs to naïve T-cells. It was determined that CTB
conjugated antigens enhanced T-cell proliferation, largely due in large to increased levels of IL12, IFN-gamma, and increased expression of the costimulatory molecules CD40 and CD86 on
the surfaces of APCs (George-Chandy et al., 2001). Furthermore, previous studies have focused
on the intracellular effects of CTB on antigen presenting cells (De Pascalis, 2012). It has since
been determined that tyrosine kinases play a significant role in the CTB induced transactivation
of transcription factor NF-κB during macrophage activation. CTB induced NF-κB transactivation
led to increased expression of CD86, MHC II, CD54, CD14, and CD40 in bone marrow-derived
macrophages. The same study established that macrophages grown in vitro increased
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secretion of the pro-inflammatory cytokine IL-6 in response to treatment with CTB (De Pascalis,
2012).

1.8 Use of CTB as a Vaccine Adjuvant in vivo
A recent in vivo study with mice, conducted by Bitsaktsis et al., has shown that CTB acts as an
effective adjuvant in experimental mucosal vaccine preparations against F. tularensis (Bitsaktsis
et al., 2009). Remarkably, these results have shown that when administered intranasally, CTB
simply mixed with inactivated F. tularensis LVS (iFt) conferred 100% protection against a lethal
challenge of Francisella tularensis live vaccine strain (FT LVS, biovar B) and partial protection
against the more virulent SchuS4 (Biovar A) strain is provided. Perhaps more interestingly, this
protection is specifically in the form of an interferon-gamma dependent Th1 response, which
completely negated the need for antibodies. This is a novel development in the use if CTB as an
adjuvant, due to the fact that the adjuvant was merely mixed with and not conjugated to the
antigen, but also on the account that the prior consensus was that CTB elicits a strictly Th2
antibody dependent response when administered intranasally (Wu and Russell,
1998);(Bromander et al., 1991);(Lycke, 1997). Additionally, the elicitation of cell-mediated
protection by a vaccine is exciting for the potential of future developments of vaccinations
against intracellular pathogens.
In this present study, an in vitro system was utilized to further elucidate the mechanisms that
drive protection against lethal FT LVS challenge in iFt+CTB immunized mice. Specifically, the
focus was directed towards determining the effects of iFt+CTB on macrophages, the common
host of F. tularensis, and their ability to present antigen to naïve T-cells, express costimulatory
14

molecules, and produce pro-inflammatory cytokines. For this purpose, populations of the
murine macrophage cell line, RAW 264.7, were exposed to experimental treatments of iFt+CTB.
We found that RAW 264.7 macrophages responded to treatment with iFt+CTB by an increased
secretion of the pro-inflammatory cytokines IL-6 and TNF-α. It was also determined that
treatment with iFt+CTB up-regulated the expression of TLR4 on the macrophage cell surface,
while treatment with iFt alone resulted in down-regulation of this receptor. The effects of
iFt+CTB treatment were shown to increase the expression of both costimulatory molecules B7.1
and B7.2 on the macrophage cell surface. Furthermore, we found that iFt+CTB enhanced the
ability of RAW 264.7 cells to present antigen to a FT-specific T-cell hybridoma cell line. These
findings allow us to elucidate in part, the mechanisms of protection against FT LVS challenge in
iFt+CTB immunized mice. Treatment with this experimental vaccine may ultimately prove the
importance of macrophages in vaccine mediated F. tularensis protection.

15

Materials and Methods
2.1 Bacteria
F. tularensis live vaccine strain (FT LVS) organisms were provided by Dr. Edmund Gosselin
(Albany Medical College, Albany, NY). F. tularensis organisms were grown in Mueller-Hinton
broth supplemented with 2% IsovitaleX™ (Fisher Scientific) enrichment to a concentration of
2.6x10⁹CFU/ml at 37°C. Live samples of F. tularensis were stored in liquid nitrogen at -80°C in
supplemented Mueller-Hinton broth.

2.2 Immunogen
Inactivated F. tularensis LVS (iFt) was used as the immunogen for these experiments. F.
tularensis bacteria were grown to a concentration of 2.6x10⁹CFU/ml in supplemented MuellerHinton broth at 37°C. 25ml of live bacteria were centrifuged and the pellet was resuspended in
25ml of 2% paraformaldehyde (PFA) and sterile PBS solution. Bacteria were fixed by an
incubation of 90 minutes in the PFA solution at room temperature while shaking. After fixation,
inactivated F. tularensis were washed three times in sterile PBS. To confirm inactivation, 100ul
of iFt (2.6x10⁸ CFU) were plated on chocolate agar plates (Fisher Scientific) and observed for
growth for seven days. Inactivated F.tularensis was stored in PBS at -20°C.

2.3 Cell Culture
The murine monocyte/macrophage cell line RAW 264.7 was provided by Dr. Allan Blake (Seton
Hall University Biology Department, South Orange, NJ). Cells were grown in RPMI 1640 media
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(Lonza) supplemented with 2mM L-Glutamine (Lonza), 10% fetal bovine serum (Lonza), and 1x
penicillin/ streptomycin (VWR International).
The FT-specific T-cell hybridoma (FT256D10) cell line was provided by Dr. Edmund Gosselin
(Albany medical College, Albany, NY). Cells were grown in RPMI 1640 media (Lonza)
supplemented with 2mM L-Glutamine (Lonza), 10% fetal bovine serum (Lonza), 1x
penicillin/streptomycin (VWR International), 1mM sodium pyruvate (Sigma), 1% MEM nonessential amino acids (Sigma), 50μM 2-mercaptoethanol (Sigma), and 1% Hygromycin (Sigma).
All cells were cultured in a humidified atmosphere of 5% CO2 at 37C.

2.4 Cytokine Measurement
RAW 264.7 cells were plated in 12 well plates at a concentration of 5x10⁵ cells per well and
allowed to incubate at 37°C in 5% CO2 for four hours. Cells were then treated with either PBS,
CTB (Sigma)(1µg/ml or 5µg/ml diluted in PBS), iFt (1x10⁵ CFU/well diluted in PBS), or a
combination of iFt (1x10⁵ CFU/well diluted in PBS) and CTB (1µg/ml or 5µg/ml diluted in PBS).
Supernatants were collected at 2 hours, 12 hours, 24 hours, or 48 hours after treatment,
depending on the nature of the cytokine being tested and stored at -20°C until analysis.
Cytokines were later measured by ELISA using ELISA Max kits (BioLegend) specific for IFN-γ,
TNF-α, IL-10, IL-4 and IL-6. All ELISA analyses were performed according to the manufacturer’s
instructions.
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2.5 Determination of cell surface markers
RAW 264.7 cells were plated in 12 well plates at a concentration of 5x10⁵ cells per well and
allowed to incubate at 37°C in 5% CO2 for four hours. Cells were then treated with either PBS,
CTB (1µg/ml or 0.5µg/ml diluted in PBS), iFt (1x10⁵ CFU/well diluted in PBS), or a combination
of iFt (1x10⁵ CFU/well diluted in PBS) and CTB (1µg/ml or 0.5µg/ml diluted in PBS). Cells were
collected after 24 hours of incubation with treatments and immediately labeled using the
following antibodies from BioLegend: Pacific Blue™ conjugated-anti-mouse CD86 (cat#105021),
Alexa Fluor® 488 conjugated-anti-mouse I-A/I-E (polymorphic determinant on I-A M
ͩ HC class II)
(cat#107615), phycoerythrin (PE) conjugated-anti-mouse CD80 (cat#104707), Alexa Fluor® 647
conjugated-anti-mouse/human CD282 (TLR2) (cat# 121809), Phycoerythrin (PE) conjugatedanti-mouse CD284 (TLR4), Pacific Blue™ conjugated-anti-mouse/human CD11b (cat#101223),
phycoerythrin (PE) conjugated-anti-mouse/human CD11b (cat#101207), and Alexa Fluor®488
conjugated-anti-mouse/human CD11b. Once labeled, cells were fixed in a solution of 2%
paraformaldehyde and FACS buffer (PBS, 5% FBS, and 0.1% sodium azide). A flow cytometer
(Macs Quant) was used to analyze fluorescent emission of tagged fluorphores.

2.6 Antigen Presentation assay
RAW 264.7 cells were plated in 12 well plates at a concentration of 5x10⁵ cells per well and
allowed to incubate at 37C in 5% CO2 for four hours. Cells were then treated with either PBS,
CTB (1µg/ml or 0.5µg/ml diluted in PBS), iFt (1x10⁵ CFU/well diluted in PBS), or a combination
of iFt (1x10⁵ CFU/well diluted in PBS) and CTB (1µg/ml or 0.5ug/ml diluted in PBS). RAW 264.7
cells were incubated with experimental vaccine treatments for 24 hours. The following day, all
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media and treatments were removed from the wells. The RAW 264.7 cells were then exposed
to the immunogen diluted in FT256D10 media. This experiment was first performed using live
FT LVS as the immunogen, then repeated using inactivated FT LVS (iFt) as the immunogen.
1x10⁶ CFU/well of live FT LVS or iFt (diluted in FT256D10 media) was added and allowed to
incubate for 15 minutes before addition of T-cells. Next, 2.5x10⁵cell/well of the FT-specific Tcell hybridoma (FT256D10) are added and allowed to incubate for 24 hours. Three additional
control groups were plated as well: macrophages with only FT LVS or iFt, macrophages with
only T-cells, and T-cells with only FT LVS or iFt. Supernatants are collected and stored at -20°C.
The T-cell hybridoma (FT256D10) secretes IL-5 upon activation. Supernatants were analyzed for
the cytokine IL-5 by ELISA using a BioLegend ELISA Max kit as per manufacturer’s instructions.

2.7 Statistical Analysis
Statistical data for cytokine analysis was generated using paired Student’s t-test comparing
concentrations of each experimental group. GraphPad Prizm 4 analysis software was used.
Flow cytometeric data was analyzed using FlowJo software.
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Results
3.1 CTB enhances the ability of the iFt immunogen to elicit secretion of pro-inflammatory
cytokines from RAW264.7 macrophages
A successful vaccine must invoke a strong immune repose in order to ultimately generate the
desired memory cells. Therefore, we wanted to determine a cytokine profile for the RAW 264.7
cells cultures with experimental vaccine treatments. The inflammatory response elicited from
the RAW 264.7 cells suggests that the macrophages were in fact stimulated by iFt+CTB as
compared to cells treated with iFt alone. This could have indicated in the very least a protective
primary response and is an encouraging result in the design of this vaccine. ELISA analysis was
performed for the pro-inflammatory cytokines IL-6, IFN-ɣ, and TNF-α. Analysis of the IL-6 ELISA
data (fig 2A and B) indicated that groups treated with CTB and iFt+CTB had an increased
secretion of IL-6 when compared to groups that were not exposed to CTB. Furthermore, groups
treated with iFt+CTB had an increased secretion of IL-6 when compared to groups treated with
only CTB. This data suggests that CTB may work synergistically with iFt to increase the
secretion of IL-6. Similarly, analysis of the TNF-α ELISA data (fig 2C and D) showed an increase
of secretion of TNF-α in groups treated with CTB and iFt+CTB as compared to groups not
exposed to CTB. However, this data proves that CTB alone drove the secretion of TNF-α and no
synergistic effect was observed in groups treated with iFt+CTB. ELISA analysis did not detect
the secretion of IFN-ɣ in any experimental group. The anti-inflammatory cytokines IL-4 and IL10 were also measured by ELISA analysis, but were not detected in any of the experimental
groups (data not shown). From these results, we can conclude that the production of these
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Figure 2. iFt+CTB has a pro-inflammatory effect on RAW 264.7 cells. Increased levels of the proinflammatory cytokines IL-6 (A and B) and TNFα (C and D) were detected by ELISA analysis in
RAW264.7 cells exposed to iFt+CTB as compared to groups treated with PBS, iFt alone, or CTB
alone. (*, p < 0.05 and **, p < 0.01, n=3)
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pro-inflammatory cytokines indicates that the macrophages are activated and capable of
driving an inflammatory response.

3.2 CTB used as an adjuvant up-regulates expression of TLR4 on RAW264.7 cells
Toll-like receptor 4 (TLR4) is a pattern recognition receptor on the surface of macrophages.
TLR4 recognizes Lipopolysaccharide (LPS), a component in the cell wall of bacteria. Ligation of
Toll-like receptors, including TLR4, is an essential signal for macrophage activation. Through
flow cytometric analysis data, we have determined that the presence of CTB in the treatment
group has led to the up-regulation of TLR4 (figure 3). Specifically, we have seen a 37.2% and
44.8% increase in TLR4 expression after 24 hours of incubation in the iFt+CTB treatment groups
as compared to the control (PBS) and iFt alone groups respectively (figure 3A,B,C, and G).
These results are further intensified after 48 hours of incubation, with an observed increase of
59.2% and 67.9% more TLR4 expression when compared to the negative control and iFt groups
respectively (Figure 3D,E,F, and G). This data also indicates a down-regulation of TLR4
expression in cells treated with iFt alone when compared to the negative control group. After
24 hours of incubation, there was a 7.6% decrease in TLR4 expression in groups treated with iFt
alone. Again these results were intensified after 48 hours of incubation, with an observed 8.7%
decrease of TLR4 expression in the cells treated with iFt alone.
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Figure 3. iFt+CTB up-regulates TLR4 expression on RAW 264.7 cells. Flow cytometric analysis
detected enhanced expression of TLR4 in cells treated with a combination of iFt and CTB (C, F
and G) when compared to treatment with PBS (A and D) or iFt alone (B and E). (*, p < 0.05 and
**, p < 0.01, n=2)
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3.3 CTB up-regulates the costimulatory cell surface molecules B7.1 (CD80) and B7.2 (CD86) on
the surface of RAW 264.7 cells
Unstimulated macrophages express low levels of the costimulatory cell surface molecules B7.1
and B7.2. These molecules provide the necessary second signal during activation of a naïve Tcell. B7.1 and B7.2 were labeled with a flourophore conjugated antibody followed by flow
cytometric analysis. The levels of B7.1/2 were determined individually along with the presence
of MHC class II, the required molecule which provides the first signal during T-cell activation.
Cells were collected after 24 and 48 hours of incubation in experimental treatments. After 24
hours of incubation, it was determined that cells treated with iFt+CTB (1µg/ml and 5µg/ml) had
a significant increase in expression of B7.1 on their cell surface (figure 4A and C). The cells
treated with a combination of iFt+CTB (at a concentration of 1µg/ml or 5µg/ml) had the most
significant increase of B7.1 expression, with 68.5% and 75.1% of cells expressing B7.1 and MHC
class II as compared to the control (PBS) (4.15% expressing both molecules) and the group
treated with iFt alone (4.91% expressing both molecules). Similar results were observed after
48 hours of incubation in experimental treatments (figure 4B and C).The cells treated with
iFt+CTB (at a concentration of 1µg/ml or 5µg/ml) had the most significant increase of B7.1
expression, with 52.0% and 68.9% of cells expressing B7.1 and MHC class II as compared to the
percentages of the cells expressing both molecules in the control (PBS) (2.81%) and iFt alone
treated groups (3.0%). The flow cytometric analysis revealed similar results for the expression
of B7.2. After 24 hours of incubation in experimental treatments (figure 5A and C), we
observed 14.1% and 18.4% of cells with dual B7.2/MHC class II expression in groups treated
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Figure 4. IFt+CTB up-regulates the expression of B7.1 on RAW 264.7 cells. Expression levels of
the costimulatory molecule B7.1 is up-regulated in groups treated with iFt+CTB at 24 hours (A
and C) and 48 hours (B and C) of incubation when compared to groups treated with PBS or iFt
alone. (*, p < 0.05 and **, p < 0.01, n=2)
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Figure 5. IFt+CTB up-regulates the expression of B7.2 on RAW 264.7 cells. Expression levels of
the costimulatory molecule B7.2 is up-regulated in groups treated with a combination of iFt and
CTB at 24 hours (A and C) and 48 hours (B and C) of incubation when compared to groups
treated with PBS or iFt alone. (*, p < 0.05 and **, p < 0.01, n=2)
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with iFt+CTB, at a concentration of 1ug/ml and 5ug/ml respectively, as compared to 5.25% dual
expression in the control and 4.31% dual expression in the iFt alone treatment group. This
same trend is further seen after 48 hours of incubation in experimental treatments (figure 5B
and C), we observed 9.76% and 22.0% of cells with dual B7.2/MHC class II expression in groups
treated with iFt+CTB, at a concentration of 1µg/ml and 5µg/ml respectively, as compared to
0.495% dual expression in the control and 0.891% dual expression in the iFt treatment group.
Though the levels of expression are not as pronounced as what was seen with B7.1 expression
there was still a statistically significant difference between the iFt+CTB treated groups as
compared to the control (PBS) and the groups treated with iFt alone. It can be concluded that
these essential costimulatory molecules are up-regulated by treatment with a combination of
iFt+CTB. Furthermore, we can deduce that CTB and iFt are working synergistically to increase
B7.1/2 expression due to the fact that cells treated with iFt alone or CTB alone (data not shown)
did not have a significant increase in expression levels. The presence of B7.1/2 on the surface
of the macrophage may enhance the cell’s ability to present antigen to a naïve T-cell.

3.4 Pretreatment of Raw 264.7 macrophages with iFt+CTB enhances antigen presentation in
vitro
After 24 hours of exposure to the same experimental vaccine treatments as previously
described on page 18, Raw264.7 cells were cultured with either live FT LVS or iFt as the antigen.
The ability of these murine macrophages to present the antigen and subsequently activate FTspecific hybridoma T-cells (FT256D10) was analyzed. FT256D10 T-cells secrete IL-5 in response
to activation. ELISA analysis was used to determine the IL-5 concentration in treatment groups.
27

When cells were cultured with iFt as the antigen, enhanced IL-5 production (>10 pg/ml) was
observed in cells pretreated with iFt+CTB as compared with cells pretreated with iFt alone
(figure 6B). This amplified secretion of IL-5 indicated that there was improved antigen
presentation occurring in these cells treated with iFt+CTB.
The experiment was repeated using live FT LVS as the antigen. Low levels of IL-5 (< 10 pg/ml)
were observed in iFt+CTB and iFt alone pretreatment groups (figure 6A). The lack of IL-5
secretion indicates a lack of successful antigen presentation occurring in all cells cultured with
live FT LVS.
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Figure 6. iFt+CTB enhances the ability of RAW264.7 cells to present antigen to a FT specific Tcell hybridoma cell line when iFt is used as the antigen. When the antigen presentation assay
was ran using live FT LVS (A) as the antigen, low levels of IL-5 were secreted in all control and
experimental treatment groups. However, when the antigen presentation assay was repeated
using iFt (B) as the antigen, enhanced secretion on IL-5 was detected in experimental groups by
ELISA analysis. Furthermore, when iFt was used as the antigen there was a significant increase
in IL-5 production in cells treated with iFt+CTB. (*, p < 0.05 and **, p < 0.01, n=3)
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Discussion
Recent in vivo studies have demonstrated that mice immunized with a combination of iFt and
CTB show a 100% survival rate following infection with a lethal challenge of FT LVS and partial
protection against the more virulent SchuS4 strain (Bitsaktsis et al., 2009). This same study
went on to further prove that this protection was IFN-ɣ dependent and could completely
negate the need for antibodies. In the present study we aimed to further elucidate the innate
mechanisms generated by this vaccine platform after exposure to the same experimental
vaccine treatment in vitro.
The pro-inflammatory cytokine production observed by the iFt+CTB treated RAW 264.7 cells
yielded promising results on the vaccine’s potential effects on macrophages. Secretion of these
pro-inflammatory cytokines indicates that these macrophages are attempting to induce
inflammation, confirming that the desired immune response is occurring in reaction to the
vaccine treatment (Kindt et al., 2007). In vivo, the acute-phase inflammatory response provides
rapid protection after tissue injury and, more importantly for this study, is crucial for clearing
invading bacteria. The healthy acute inflammatory response is the first line of defense after
exposure to a pathogen, it should be quickly activated, clear the pathogen, and cease. On the
local level, inflammation is characterized by redness, swelling, pain, heat, and loss of function.
Immediately at the site of injury/infection, vasodilation and increased vascular permeability
occurs, allowing for greater blood flow and leakage of fluids from the blood. The inflammatory
process is a positive feedback driven chain reaction event. The edema in the affected tissue
causes multiple enzymatic cascades to initiate, including the bradykinin, fibirin, and plasmin
systems, further triggering vascular permeability as well as complement activation (Kindt et al.,
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2007). Complement system activation will induce mast cell degranulation, releasing histamine
an extremely powerful mediator of inflammation. After a few hours, these vascular changes
will provoke neutrophils to extravasate out of the blood vessels and into the tissue, where they
begin to phagocytose pathogens, release further mediators of inflammation, and secrete
chemokines. These chemokines will attract activated macrophages to the site of infection,
about 5-6 hours after initial injury/infection. Activated macrophages have an increased ability
to phagocytose and kill pathogens, as well as secrete three characteristic cytokines, TNF-α, IL-1,
and IL-6, all of which further propagate the inflammatory response. TNF-α is an extremely
powerful mediator of inflammation, which displays multiple actions during the acute phase
response. Increased expression of E-selectin, an endothelial cell adhesion molecule that
specifically adheres to adhesion molecules on neutrophils, is observed in the presence of TNFα. TNF-α also promotes the further secretion of chemokines from macrophages and
endothelial cells, which recruit added neutrophils to the site (Kindt et al., 2007). Moreover,
TNF-α along with IFN-ɣ activate naïve macrophages and neutrophils, resulting in enhanced
phagocytosis and secretion of lytic enzymes in the affected tissue. IL-6, at the site of infection,
induces the release of IL-8, another chemokine that attracts neutrophils, basophils, and some
subpopulations of lymphocytes. These changes induced by the inflammatory response at the
local level result in the accumulation of lymphocytes, monocytes, neutrophils, eosinophils,
basophils, and mast cells at the site of injury/infection, which are successful in clearing the
invading pathogen in most cases. While the inflammatory response occurs at the local level, a
systemic inflammatory response takes place. The systemic inflammatory response is
characterized by fever, hormone secretion, namely ACTH and hydrocortisone, increased
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production of white blood cells, and emission of acute phase proteins by the liver. Most of
these systemic changes are similarly due to the combined effects of TNF-α, IL-6, and IL-1.
The secretion of IL-6 in response to treatment with CTB has been previously documented in
bone marrow derived macrophages (De Pascalis, 2012). Therefore, the increased secretion of
IL-6 observed by iFt+CTB treated RAW264.7 cells was expected and could have signaled that the
desired immune response to the experimental vaccine had indeed occurred. However, there is
a marked increase of IL-6 secretion in cells treated with a combination of iFt+CTB when
compared with cells treated with CTB alone. This signifies that iFt+CTB are working
synergistically to increase the amount of IL-6 produced, and that this level of secretion was not
simply a response to the presence of CTB. This is a desired effect in an adjuvant, for an
adjuvant alone should not induce an immune response (Bitsaktsis et al., 2009).
The increased secretion of TNF-α also indicated that the desired immune response was
occurring upon treatment with CTB. However the data established that the response was
driven by the CTB alone, and was not correlated to the presence of iFt.
It is important to note, that only activated macrophages are able to secrete pro-inflammatory
cytokines, which raises the question of RAW 264.7 cell activation. Macrophages are classically
activated by two signals; TLR ligation followed by the action IFN-ɣ (Mosser, 2003). In the
present study, ELISA analysis has shown that there is no detectable IFN-ɣ present in the
treatment wells (data not shown). This may prove a method of adjuvanticity exerted by the
CTB, which may itself be acting as a second signal to activate macrophages negating the need
for IFN-ɣ.
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Interestingly, this data (Figure 3B, E, and G) has indicated a down-regulation of TLR4 in the iFt
alone treated cells. Francisella tularensis is known to have immunosuppressing properties,
previous studies have established that macrophages infected with the live FT Schu4 strain do
experience TLR4 down-regulation; however this has not been documented after exposure to iFt
(Butchar et al., 2008). The continued ability of iFt to down-regulate TLR4 is significant and the
mechanisms by which this occurs have yet to be determined. The up-regulation of TLR4 seen in
the iFt+CTB treated groups is one of the adjuvant effects conferred by CTB, and may account
for the synergistic effect observed in the increased IL-6 secretion of iFt+CTB treated groups.
Increased expression of TLR4 would allow for a higher number of receptors present on the
surface of the cell to be ligated with LPS, and thus increase the likelihood for macrophage
activation and subsequently increase IL-6 secretion.
Macrophages are typically unable to activate naïve T-cells. This is a protective mechanism due
to the fact that macrophages continuously scavenge dead, or senescent host cells and the
presentation of a self-antigen to T-cells could result in autoimmune disease (Janeway and
Travers, 1994). Though they are the most inept APC they can efficiently and reliably present
antigen after exposure to microbial elements in the proper cytokine milieu. Macrophages must
become activated in order to process and present antigen to T-cells and express the mandatory
costimulatory molecules. As mentioned above, macrophages classically need two signals to
activate (Mosser, 2003). The first signal is the essential cytokine IFN-gamma, usually secreted
by T-lymphocytes, this cytokine primes the macrophage for activation, but does not activate
the cell itself. The second signal is tumor necrosis factor (TNF), which is typically endogenously
produced by the macrophage itself, following ligation of various Toll-like receptors by assorted
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microbial products. Only activated macrophages are able to produce pro-immune response
cytokines such as TNF-α, IL-12, IL-6, and IL-1 and generate toxic antimicrobial oxygen and
nitrogen species such as NO and O2-. On the contrary, macrophages exposed to IL-4 or
glucocorticoids assume an “alternatively activated” phenotype. These alternatively activated
macrophages act much differently than the classically activated macrophage. These cells do
not make NO or O2- and are unable to clear intracellular pathogens. Performing more as
immune-regulatory cells, they are not efficient at presenting antigen to naïve T-cells and may in
fact inhibit T-cell proliferation. Recent studies have shown that live FT LVS has the ability to
shift classically activated macrophages to the alternatively activated phenotype in vitro as well
as in vivo (Shirey et al., 2008). This may account for the lack of antigen presentation seen
during the antigen presentation assay when live FT LVS was cultured with the cells.
Furthermore, when iFt was used as the antigen, enhanced antigen presentation was seen in all
experimental groups demonstrating that the live bacterium could be negatively influencing the
macrophage’s ability to present antigen. In addition to the enhanced antigen presentation
seen in all experimental groups, there was a significant increase in antigen presentation of
macrophages treated with iFt+CTB. It is plausible to conclude that this improved presentation
may be due to the observed increased expression of the two costimulatory molecules B7.1 and
B7.2 in response to treatment with iFt+CTB. It also reinforces the notion that vaccine
preparations against Francisella tularensis should only utilize inactivated organisms or subunits,
and not live attenuated preparations. The increased expression of B7.1/2 detected along with
the presence of the MHC class II molecule on the surface of these macrophages confirms that
they are equipped and able to activate naïve T-cells and consequently generate T-memory cells.
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The ability of iFt+CTB to activate macrophages, up-regulate key cell surface molecules, provoke
the secretion of pro-inflammatory cytokines, and improve antigen presentation, may lead to
the hypothesis that it may be the enhanced activity of the macrophage that is contributing to
the 100% survival rate previously granted by iFt+CTB in in vivo. However, the ability of live FT
LVS to negatively impact antigen presentation by macrophages in vitro, leads to the conclusion
that their involvement in vaccine granted protection is strictly innate. The ability of live FT LVS
to counteract the iFt+CTB granted ability for macrophages to successfully present antigen to FTspecific T-cells clarifies that it is not primarily the macrophage that generates a protective
adaptive immune response.
This leads us to hypothesize that the dendritic cell (DC), the most proficient antigen presenting
cell, may be key to the previously observed protection in vivo. Currently studies are being
conducted to elucidate the potential effects of iFt+CTB immunization on dendritic cells and to
further understand the mechanisms that mediate protection in this vaccine platform.

35

References

1. Bioterrorism agents/diseases. (n.d.). Retrieved from http://www.bt.cdc.gov/agent/agentlistcategory.asp
2. Bitsaktsis, C., Deepak, R. B., Li, Y., Kurkure, N. V., Iglesias, B., & Gosselin, E. J. (2009). Differential
requirements for protection against mucosal challenge with francisella tularensis in the
presence versus absence of cholera toxin b and inactivated f. tularensis. The Journal of
Immunology, 182, 4899-4909.
3. Bromander, A., Holmgren, J., & Lyckr, N. (1991). Cholera toxin stimulates il-1 production and
enhances antigen presentation by macrophages in vitro. The Journal of Immunology, 146(9),
2908-2914.
4. Butchar JP, Cremer TJ, Clay CD, Gavrilin MA, Wewers MD, et al. (2008) Microarray Analysis of
Human Monocytes Infected with Francisella tularensis Identifies New Targets of Host Response
Subversion. PLoS ONE 3(8): e2924. doi:10.1371/journal.pone.0002924
5. Clem, A. S. (2011). Fundamentals of vaccine immunology. Journal of Global Infectious Diseases,
3(1), 73-78.
6. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D.,
& et al. (2001). Tularemia as a biological weapon: Medical and public health management. The
Journal of the American Medical Association, 285(21), 2763-2773. Retrieved from
http://jama.ama-assn.org/
7. De Pascalis, R. (2012). Development of functional and molecular correlates of vaccine-induced
protection for model intracellular pathogen, f. tularensis lvs. PLoS Pathogens, 8(1), doi:
10.1371/journal.ppat.1002494
8. George-Chandy, A., Eriksson, K., Lebens, M., Nordstrom, I., Schon, E., & Holmgren, J. (2001).
Cholera toxin b as a carrier molecule promotes antigen presentation and increases cd40 and
cd86 expression an antigen-presenting cells. Infection and Immunology, 69(9), 5716-5725. doi:
10.1128/IAI69.9.5716-5725.2001
9. Harvey, R. A., Champe, P. C., & Fisher, B. D. (2007). Microbiology. (2 ed., pp. 141-144).
Baltimore: Lipponcott Williams & Wilkins.
10. Janeway, C. A., & Travers, P. (1994). Immunobiology; the immune system in health and disease.
(pp. 712-715). New York: Garland Publishing Inc.
11. Kindt, T. J., Goldsby, R. A., & Osborne, B. A. (2007). Kuby immunology . (6 ed., pp. 80-81). New
York: W.H. Freeman and Company.
12. Kraehenbuhl, J. P., & Neutra, M. R. (1999). Defense of mucosal surfaces: Pathogenesis,
immunity, and vaccines. (pp. 1-19). Berlin: Springer-Verlag.
13. Lycke, N. (1997). The mechanism of cholera toxin adjuvanticity. 72nd Forum of Immunology,
504-520.
14. MacDonald, T., Smith, P., & Blumburg, R. (2013). Principles of mucosal immunology. (pp. 1-18).
New York, NY: Garland Science.
36

15. Mosser, D. M. (2003). The many faces of macrophage activation. Journal of Leukocyte Biology,
73, 209-212. doi: 10.1189/jlb.0602325
16. Rappuoli, R., Pizza, M., Douce, G., & Dougan, G. (1999). Structure and mucosal adjuvanticity of
cholera and escherichia coli heat-labile enterotoxins. Immunology Today, 20(11), 493-500.
17. Rhee, J. H., & Lee, S. E. (2012). Mucosal vaccine adjuvants update. Clinical and Experimental
Vaccine Research, 1, 50-63. doi: 10.7774/cevr.2012.1.1.50
18. Shirey, K., Cole, L., Keegan, A., & Vogel, S. (2008). Francisella tularensis live vaccine strain
induces macrophage alternative activation as a survival mechanism. Journal of immunology,
181, 4159-4167.
19. Wong, D., & Shapiro, S. (1999). Manual of clinical microbiology. (7 ed., pp. 647-651). Washington
D.C.: American Society for Microbiology Press.
20. Wu, H., & Russell, M. W. (1998). Induction of mucosal immune responses by intranasal
immunization using recombinant cholera toxin b subunit as an adjuvant. Vaccine, 16(2/3), 286292.
21. Yuki, Y., & Kiyono, H. (2003). New generation of mucosal adjuvants for the induction of
protective immunity. Reviews in Medical Virology, 13, 293-310. doi: 10.1002/rmv.398

37

